Nilotinib Price is the primary procurement benchmark that hospital formulary committees, licensed pharmaceutical importers, and oncology medicine distributors across Nigeria, South Africa, Ghana, Benin, Niger, Cameroon, Chad, and Egypt evaluate before entering any business-to-business supply agreement for this second-generation tyrosine kinase inhibitor. As demand for targeted CML therapies continues to grow across Sub-Saharan and North African markets, understanding the fact